Aranesp Related Published Studies
Well-designed clinical trials related to Aranesp (Erythropoiesis Stimulating Protein)
The Primavera study protocol design: evaluating the effect of continuous erythropoiesis receptor activator (C.E.R.A.) on renal function in non-anemic patients with chronic kidney disease. [2011.11]
Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009. [2011.05]
Are there implications from the Trial to Reduce Cardiovascular Events with Aranesp Therapy study for anemia management in dialysis patients? [2010.11]
Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. [2010.09]
Are there implications from the Trial to Reduce Cardiovascular Events with Aranesp Therapy study for anemia management in dialysis patients? [2010.07.01]
Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol. [2010.06.09]
Erythropoiesis stimulating agent administration improves survival after severe traumatic brain injury: a matched case control study. [2010.01]
Effect of synthetic vitamin E-bonded membrane on responsiveness to erythropoiesis-stimulating agents in hemodialysis patients: a pilot study. [2010]
Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). [2009.07]
Challenge of effectively using erythropoiesis-stimulating agents and intravenous iron. [2008.12]
Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial. [2006.05]
Rationale--Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): evolving the management of cardiovascular risk in patients with chronic kidney disease. [2005.03]
Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. [2001.08]
Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. [1999.11]
Optimal timing of repeated rh-erythropoietin administration improves its effectiveness in stimulating erythropoiesis in healthy volunteers. [1996.02]
Well-designed clinical trials possibly related to Aranesp (Erythropoiesis Stimulating Protein)
Testosterone induces erythrocytosis via increased erythropoietin and suppressed
hepcidin: evidence for a new erythropoietin/hemoglobin set point. [2014]
Assessing the effect of darbepoetin alfa on patient-reported fatigue in chemotherapy-induced anemia in four randomized, placebo-controlled clinical trials. [2011.06.05]
Very low birth weight infants qualifying for a 'late' erythrocyte transfusion: does giving darbepoetin along with the transfusion counteract the transfusion's erythropoietic suppression? [2011.04]
Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial. [2011.04]
A multicenter, prospective, randomized, controlled trial evaluating the safety and efficacy of intracoronary cell infusion mobilized with granulocyte colony-stimulating factor and darbepoetin after acute myocardial infarction: study design and rationale of the 'MAGIC cell-5-combination cytokine trial'. [2011.02.07]
Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. [2011.01.01]
Addition of darbepoetin alfa to dose-dense chemotherapy: results from a randomized phase II trial in small-cell lung cancer patients receiving carboplatin plus etoposide. [2011.01]
A novel amino acids oral supplementation in hemodialysis patients: a pilot study. [2011]
[Diagnosis and treatment of anemia in heart failure patients]. [Article in Italian] [2011]
Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial. [2010.12]
Impact of haemoglobin and erythropoietin dose changes on mortality: a secondary analysis of results from a randomized anaemia management trial. [2010.12]
A prospective protocol-based trial of darbepoetin alfa therapy to correct the early anemia following renal transplantation. [2010.11]
Internal hemodiafiltration versus low-flux bicarbonate dialysis: Results from a long-term prospective study. [2010.11]
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. [2010.11]
Comparison of darbepoetin alfa dosed weekly (QW) vs. extended dosing schedule (EDS) in the treatment of anemia in patients receiving multicycle chemotherapy in a randomized, phase 2, open-label trial. [2010.10.25]
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. [2010.09.16]
What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level? [2010.09]
Darbepoetin alfa 300 or 500 mug once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. [2010.09]
Diabetes, anemia and CKD: Why TREAT? [2010.08]
Randomized phase 2 dose-finding study of weekly administration of darbepoetin alpha in anemic patients with lung or ovarian cancer receiving multicycle platinum-containing chemotherapy. [2010.06]
Randomized trial of model predictive control for improved anemia management. [2010.05]
Intravenously administered darbepoetin alfa once a week could maintain hemoglobin level more efficiently than once every 2 weeks in patients on hemodialysis. [2010.04]
C.E.R.A. once every 4 weeks in patients with chronic kidney disease not on dialysis: The ARCTOS extension study. [2010.04]
Dialysis patients treated with Epoetin alfa show improved anemia symptoms: A new analysis of the Canadian Erythropoietin Study Group trial. [2010.04]
Use of latent growth curve models for assessing the effects of darbepoetin alfa on hemoglobin and fatigue. [2010.03]
Maintaining high hemoglobin levels improved the left ventricular mass index and quality of life scores in pre-dialysis Japanese chronic kidney disease patients. [2010.02]
C.E.R.A. safety profile: a pooled analysis in patients with chronic kidney disease. [2010.02]
Treatment of anemia with darbepoetin alfa in heart failure. [2010]
Dialysis patients treated with Epoetin alfa show improved anemia symptoms: A new
analysis of the Canadian Erythropoietin Study Group trial. [2010]
Randomized trial of model predictive control for improved anemia management. [2010]
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. [2009.11.19]
Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. [2009.11]
Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial. [2009.09.03]
Randomized, double-blind, placebo-controlled trial of every-3-week darbepoetin alfa 300 micrograms for treatment of chemotherapy-induced anemia. [2009.09]
Immediate pain sensation is less with subcutaneous epoietin-beta compared to subcutaneous darbepoietin-alpha. [2009.09]
Effect of computer-assisted European Best Practice Guideline implementation on adherence and target attainment: ORAMA results. [2009.09]
Rationale and design of the oral HEMe iron polypeptide Against Treatment with Oral Controlled Release Iron Tablets trial for the correction of anaemia in peritoneal dialysis patients (HEMATOCRIT trial). [2009.07.28]
Biosimilarity of HX575 (human recombinant epoetin alfa) and epoetin beta after multiple subcutaneous administration. [2009.06]
Effects of Darbepoetin Alfa on plasma mediators of oxidative and nitrosative stress in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. [2009.04.15]
HX575, recombinant human epoetin alfa, for the treatment of chemotherapy-associated symptomatic anaemia in patients with solid tumours. [2009.04]
Erythropoietin therapy, hemoglobin targets, and quality of life in healthy hemodialysis patients: a randomized trial. [2009.04]
Randomized equivalence study evaluating the possibility of switching hemodialysis patients receiving subcutaneous human erythropoietin directly to intravenous darbepoetin alfa. [2009.02]
Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patients. [2009.02]
Erythropoietin Treatment in Patients with Chronic Heart Failure: a meta-analysis. [2009.01.23]
Effect of FX dialysers on systemic inflammation and quality of life in chronic haemodialysis patients. [2009]
Mobilization effects of G-CSF, GM-CSF, and darbepoetin-alpha for allogeneic peripheral blood stem cell transplantation. [2009]
Hemoglobin targets and blood transfusions in hemodialysis patients without symptomatic cardiac disease receiving erythropoietin therapy. [2008.11]
Development of a fatigue and functional impact scale in anemic cancer patients receiving chemotherapy. [2008.09.15]
Effects of aerobic exercise training in anemic cancer patients receiving darbepoetin alfa: a randomized controlled trial. [2008.09]
Oxpentifylline versus placebo in the treatment of erythropoietin-resistant anaemia: a randomized controlled trial. [2008.08.01]
Effects of darbepoetin-alpha on plasma pro-inflammatory cytokines, anti-inflammatory cytokine interleukin-10 and soluble Fas/Fas ligand system in anemic patients with chronic heart failure. [2008.07]
ORAMA: a study to investigate EBPG impact on renal anaemia - design and baseline data. [2008.07]
A trial comparing local pain after subcutaneous injection of epoetin-beta versus darbepoetin-alpha in healthy volunteers. [2008.07]
Effects of darbepoetin-alpha on quality of life and emotional stress in anemic patients with chronic heart failure. [2008.06]
Safety and efficacy of darbepoetin alpha in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. [2008.05.10]
Efficacy and safety of once-weekly intravenous epoetin alfa in maintaining hemoglobin levels in hemodialysis patients. [2008.05]
Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. [2008.04.01]
Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. [2008.04.01]
Effects of darbepoetin alpha on right and left ventricular systolic and diastolic function in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. [2008.04]
Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. [2008.03.01]
Randomized double-blind trial of darbepoetin alfa in patients with symptomatic heart failure and anemia. [2008.01.29]
Subcutaneous injection pain with C.E.R.A., a continuous erythropoietin receptor activator, compared with darbepoetin alfa. [2007.12]
Efficacy of intravenous methoxy polyethylene glycol-epoetin beta administered every 2 weeks compared with epoetin administered 3 times weekly in patients treated by hemodialysis or peritoneal dialysis: a randomized trial. [2007.12]
Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration. [2007.11]
Intravenous methoxy polyethylene glycol-epoetin beta for haemoglobin control in patients with chronic kidney disease who are on dialysis: a randomised non-inferiority trial (MAXIMA). [2007.10.20]
A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia. [2007.10]
The effect of 4 wk of oral echinacea supplementation on serum erythropoietin and indices of erythropoietic status. [2007.08]
Efficacy and safety of every-2-week darbepoetin alfa in patients with anemia of cancer: a controlled, randomized, open-label phase II trial. [2007.06]
Darbepoetin alfa effectively maintains hemoglobin concentrations at extended dose intervals relative to intravenous rHuEPO in Japanese dialysis patients. [2007.06]
A randomized, controlled trial comparing darbepoetin alfa correction/maintenance dosing with weekly dosing for treating chemotherapy-induced anemia. [2007.06]
Cognitive function during neoadjuvant chemotherapy for breast cancer: results of a prospective, multicenter, longitudinal study. [2007.05.01]
Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. [2007.05]
The continuous erythropoietin receptor activator (C.E.R.A.) corrects anemia at extended administration intervals in patients with chronic kidney disease not on dialysis: results of a phase II study. [2007.05]
Darbepoetin alfa once every 2 weeks for treatment of anemia in dialysis patients: a combined analysis of eight multicenter trials. [2007.03]
Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapy. [2007.03]
Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. [2007.03]
Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial. [2007.02.20]
Increased injection pain with darbepoetin-alpha compared to epoetin-beta in paediatric dialysis patients. [2006.12]
Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study. [2006.12]
Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (C.E.R.A.) in patients with chronic kidney disease. [2006.11]
Ultrapure dialysate and inflammatory response in haemodialysis evaluated by darbepoetin requirements--a randomized study. [2006.10]
Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy. [2006.09.01]
Does granulocyte colony-stimulating factor worsen anemia in early breast cancer patients treated with epirubicin and cyclophosphamide? [2006.07.01]
A randomized, controlled trial of the effects of adding vitamin B12 and folate to erythropoietin for the treatment of anemia of prematurity. [2006.07]
Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. [2006.05.20]
Clinical implications of converting stable haemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa. [2006.05]
|